- You can view the full Regeneron Pharmaceuticals Ratings Report.
- Use our health care section to find sector-relevant news.
- Or find some new ideas from our top rated stocks lists.
- Find other investment ideas from our top rated ETFs lists.
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) said today that trials of their cholesterol drug Praulent met targets.
Pfizer's $14 billion acquisition of Medivation is a strong purchase, according to Jim Cramer, who now wonders what Sanofi will do next.
Trade-Ideas LLC identified Regeneron Pharmaceuticals (REGN) as an unusual social activity candidate